BRPI0813313A2 - Vetor poxvírus de racum recombinante, vacina da raiva recombinante, métodos para induzir uma resposta imunoprotetora para a raiva em um mamífero, e para produzir um vetor poxvírus de racum recombinante, e, plasmídeo pfd2003-gpv-pv. - Google Patents

Vetor poxvírus de racum recombinante, vacina da raiva recombinante, métodos para induzir uma resposta imunoprotetora para a raiva em um mamífero, e para produzir um vetor poxvírus de racum recombinante, e, plasmídeo pfd2003-gpv-pv.

Info

Publication number: BRPI0813313A2
Authority: BR; Brazil
Prior art keywords: recombinant; racum; poxvirus vector; paspv200; immunotive
Prior art date: 2007-05-30

Application number

BRPI0813313-1A2A

Other languages

English (en)

Inventor

Stephen Qitu Wu

Michael A Gill

Hsien-Jue Chu

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-30

Filing date

2008-05-28

Publication date

2014-12-23

2008-05-28 Application filed by Wyeth Corp filed Critical Wyeth Corp

2014-12-23 Publication of BRPI0813313A2 publication Critical patent/BRPI0813313A2/pt

2016-04-19 Publication of BRPI0813313A8 publication Critical patent/BRPI0813313A8/pt

Links

239000013598 vector Substances 0.000 title 2
241001465754 Metazoa Species 0.000 title 1
206010037742 Rabies Diseases 0.000 title 1
230000001939 inductive effect Effects 0.000 title 1
238000000034 method Methods 0.000 title 1
230000004044 response Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

BRPI0813313A 2007-05-30 2008-05-28 Vetor poxvírus de racum recombinante, vacina da raiva recombinante, métodos para induzir uma resposta imunoprotetora para a raiva em um mamífero, e para produzir um vetor poxvírus de racum recombinante, e, plasmídeo pfd2003-gpv-pv. BRPI0813313A8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US93249207P	2007-05-30	2007-05-30
PCT/US2008/006736 WO2008153794A1 (en)	2007-05-30	2008-05-28	Raccoon poxvirus expressing rabies glycoproteins

Publications (2)

Publication Number	Publication Date
BRPI0813313A2 true BRPI0813313A2 (pt)	2014-12-23
BRPI0813313A8 BRPI0813313A8 (pt)	2016-04-19

Family

ID=40130030

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0813313A BRPI0813313A8 (pt)	2007-05-30	2008-05-28	Vetor poxvírus de racum recombinante, vacina da raiva recombinante, métodos para induzir uma resposta imunoprotetora para a raiva em um mamífero, e para produzir um vetor poxvírus de racum recombinante, e, plasmídeo pfd2003-gpv-pv.

Country Status (17)

Country	Link
US (1)	US8795681B2 (pt)
EP (2)	EP2150624B1 (pt)
JP (1)	JP5653751B2 (pt)
KR (1)	KR20100031523A (pt)
CN (1)	CN101680036B (pt)
AR (1)	AR066813A1 (pt)
AU (1)	AU2008263208B8 (pt)
BR (1)	BRPI0813313A8 (pt)
CA (1)	CA2681454C (pt)
CL (1)	CL2008001543A1 (pt)
CO (1)	CO6140071A2 (pt)
MX (1)	MX2009012597A (pt)
NZ (1)	NZ597773A (pt)
PH (1)	PH12013501116A1 (pt)
TW (1)	TW200907058A (pt)
WO (1)	WO2008153794A1 (pt)
ZA (1)	ZA200908390B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN107375919B (zh)	2009-03-27	2022-07-29	台湾地区“中央研究院”	抗病毒免疫的方法和组合物
CN102344913B (zh) *	2010-07-30	2013-07-03	中国农业科学院哈尔滨兽医研究所	表达狂犬病病毒g蛋白重组犬瘟热病毒cdv/r-20/8疫苗株的构建
KR101847908B1 (ko)	2010-11-05	2018-04-11	노바백스, 인코포레이티드	광견병 당단백질 바이러스-유사 입자(VLPs)
KR101479668B1 (ko) *	2012-07-31	2015-01-12	대한민국	광견병 바이러스 유전자를 발현하는 재조합 아데노바이러스 및 이를 포함하는 광견병의 예방 또는 치료용 백신 조성물
US11013798B2 (en)	2016-03-21	2021-05-25	South Dakota Board Of Regents	Orf virus-based platform for vaccine delivery
US11992526B2 (en) *	2017-11-06	2024-05-28	Intervet Inc.	Rabies virus vaccine
KR102712874B1 (ko) *	2021-07-02	2024-10-04	주식회사 바이오에프디엔씨	고주파 특이적 발현 프로모터
CN116621949B (zh) *	2023-04-25	2024-01-30	华南生物医药研究院	一种增加狂犬病毒g蛋白分泌表达的方法及应用
CN116656730B (zh) *	2023-05-25	2024-03-19	军事科学院军事医学研究院军事兽医研究所	一种表达狂犬病病毒g、m蛋白的重组金丝雀痘病毒及其构建方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5338683A (en)	1981-12-24	1994-08-16	Health Research Incorporated	Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US7045313B1 (en)	1982-11-30	2006-05-16	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5047238A (en)	1983-06-15	1991-09-10	American Home Products Corporation	Adjuvants for vaccines
US5830477A (en)	1984-04-25	1998-11-03	Transgene S.A.	Vaccine against rabies and process for preparation thereof
FR2563434B1 (fr)	1984-04-25	1986-07-25	Transgene Sa	Vaccin contre la rage et procede pour sa preparation
US5348741A (en)	1987-02-03	1994-09-20	The United States Of America As Represented By The Department Of Health And Human Services	Vector for recombinant poxvirus expressing rabies virus glycoprotein
US5266313A (en)	1987-02-03	1993-11-30	The United States Of America As Represented By The Department Of Health And Human Services	Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms
US7087234B1 (en)	1991-07-09	2006-08-08	Cornell Research Foundation, Inc.	Recombinant multivalent viral vaccine
US6241989B1 (en) *	1991-07-09	2001-06-05	Cornell Research Foundation, Inc.	Recombinant multivalent viral vaccine
US6106841A (en)	1998-02-04	2000-08-22	Heska Corporation	Delivery method for recombinant raccoon poxvirus
FR2775601B1 (fr) *	1998-03-03	2001-09-21	Merial Sas	Vaccins vivants recombines et adjuves
US6294176B1 (en) *	1998-07-10	2001-09-25	Schering-Plough Veterinary Corp.	Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
ES2283150T3 (es)	1998-11-27	2007-10-16	Intervet International Bv	Mutantes del virus de la rabia atenuados estables y vacunas vivas de los mismos.
US6673601B1 (en) *	1999-04-15	2004-01-06	Institut Pasteur	Chimeric lyssavirus nucleic acids and polypeptides
AR023505A1 (es)	1999-04-15	2002-09-04	Pasteur Institut	Un vector de expresion que contiene una secuencia polinucleotidica que codifica en parte una glicoproteina de lyssavirus, polipeptidos y una composicion inmunogenica.
WO2000073479A1 (en)	1999-05-28	2000-12-07	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
WO2001070932A2 (en)	2000-03-23	2001-09-27	Thomas Jefferson University	Genetically engineered rabies recombinant vaccine for immunization of stray dogs and wildlife
US6962810B2 (en)	2000-10-31	2005-11-08	University Of Notre Dame Du Lac	Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac
AU2003241267A1 (en)	2002-01-08	2003-09-22	Siga Technologies, Inc.	Screening method for orthopoxvirus antivirals
ATE315660T1 (de) *	2002-05-16	2006-02-15	Bavarian Nordic As	Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva)
CA2571316A1 (en)	2004-06-21	2006-01-05	Merial Limited	Vaccination of skunks and/or mongooses against rabies

2008
- 2008-05-26 TW TW097119415A patent/TW200907058A/zh unknown
- 2008-05-28 EP EP08767903.1A patent/EP2150624B1/en active Active
- 2008-05-28 WO PCT/US2008/006736 patent/WO2008153794A1/en not_active Ceased
- 2008-05-28 KR KR1020097027378A patent/KR20100031523A/ko not_active Abandoned
- 2008-05-28 CN CN200880017695.7A patent/CN101680036B/zh not_active Expired - Fee Related
- 2008-05-28 NZ NZ597773A patent/NZ597773A/xx not_active IP Right Cessation
- 2008-05-28 CL CL200801543A patent/CL2008001543A1/es unknown
- 2008-05-28 EP EP20120185716 patent/EP2540314A1/en not_active Withdrawn
- 2008-05-28 US US12/128,296 patent/US8795681B2/en active Active
- 2008-05-28 JP JP2010510318A patent/JP5653751B2/ja not_active Expired - Fee Related
- 2008-05-28 MX MX2009012597A patent/MX2009012597A/es active IP Right Grant
- 2008-05-28 CA CA2681454A patent/CA2681454C/en active Active
- 2008-05-28 BR BRPI0813313A patent/BRPI0813313A8/pt not_active IP Right Cessation
- 2008-05-28 AU AU2008263208A patent/AU2008263208B8/en active Active
- 2008-06-02 AR ARP080102316A patent/AR066813A1/es not_active Application Discontinuation
2009
- 2009-11-23 CO CO09133041A patent/CO6140071A2/es unknown
- 2009-11-26 ZA ZA2009/08390A patent/ZA200908390B/en unknown
2013
- 2013-05-31 PH PH12013501116A patent/PH12013501116A1/en unknown

Also Published As

Publication number	Publication date
CL2008001543A1 (es)	2008-07-25
NZ597773A (en)	2013-05-31
EP2540314A1 (en)	2013-01-02
PH12013501116A1 (en)	2016-02-01
EP2150624A4 (en)	2010-10-13
AR066813A1 (es)	2009-09-16
ZA200908390B (en)	2010-08-25
AU2008263208A1 (en)	2008-12-18
KR20100031523A (ko)	2010-03-22
HK1142370A1 (en)	2010-12-03
MX2009012597A (es)	2009-12-07
JP2010528605A (ja)	2010-08-26
EP2150624B1 (en)	2015-07-08
CA2681454A1 (en)	2008-12-18
BRPI0813313A8 (pt)	2016-04-19
CN101680036B (zh)	2014-03-05
CA2681454C (en)	2018-01-30
CO6140071A2 (es)	2010-03-19
US8795681B2 (en)	2014-08-05
AU2008263208B2 (en)	2012-04-19
WO2008153794A1 (en)	2008-12-18
AU2008263208B8 (en)	2012-08-16
TW200907058A (en)	2009-02-16
JP5653751B2 (ja)	2015-01-14
EP2150624A1 (en)	2010-02-10
US20090010963A1 (en)	2009-01-08
CN101680036A (zh)	2010-03-24

Legal Events

Date	Code	Title	Description
2016-03-08	B25D	Requested change of name of applicant approved	Owner name: WYETH LLC (US)
2016-03-29	B25A	Requested transfer of rights approved	Owner name: PAH W LLC (US)
2016-04-19	B25D	Requested change of name of applicant approved	Owner name: ZOETIS W LLC (US)
2017-03-28	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2017-07-11	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2412 DE 28-03-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0813313A2 (pt)	2014-12-23	Vetor poxvírus de racum recombinante, vacina da raiva recombinante, métodos para induzir uma resposta imunoprotetora para a raiva em um mamífero, e para produzir um vetor poxvírus de racum recombinante, e, plasmídeo pfd2003-gpv-pv.
LTPA2020539I1 (lt)	2021-01-11	1'-Pakeistieji karba-nukleozidų analogai, skirti antivirusiniam gydymui
BR112013015898A2 (pt)	2018-06-26	derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
BRPI0909436A2 (pt)	2015-12-15	dsitribuidor de turbina para uma turbomáquina, turbina de turbomáquina e turbomáquina
NL2003118A1 (nl)	2010-01-18	Alignment system, lithographic system and method.
DK2307543T3 (da)	2015-08-31	Forbedret proteinekspressionssystem
BRPI0918324A2 (pt)	2016-08-23	máscara de dormir, método para fornecer terapia de luz a um indivíduo, máscara configurada para fornecer terapia de luz a um indivíduo
DK2616102T3 (da)	2019-07-29	Prodrugs, som omfatter et exendin-linker-konjugat
EP2056861A4 (en)	2012-04-25	IMPF-IMMUNOTHERAPY
BRPI0909122A2 (pt)	2015-11-24	métodos para produzir produtos estiráveis.
BRPI0914145A2 (pt)	2015-10-20	métodos para produzir polimerização por radical controlada, e para obter distribuição por radical atva controlada.
EP2647644A4 (en)	2014-05-14	2'-O-MODIFIED RNA
BRPI0923801A2 (pt)	2015-07-21	Métodos para produzir um éster, e para produzir amidas.
EP1991262A4 (en)	2009-11-04	MYCOPLASMA HYOPNEUMONIAE VACCINE
BR112012024432A2 (pt)	2016-05-31	composição farmacêutica de dissolução rápida
BRPI0810710A2 (pt)	2014-10-21	Método para estabilização de uma proteína.
DK2344471T3 (da)	2013-10-07	7-piperidinalkyl-3,4-dihydroquinolon-derivat
NL2003100A1 (nl)	2009-12-29	Track system with adjustable width.
BRPI0818531A2 (pt)	2014-10-14	Poloinucleotídeo, proteína, vetor, transformante, métodos para produzir a protéina e uma glucuronida
DK2307020T3 (da)	2019-05-13	Administrationsskema til nitrocatecholer
BRPI0912762A2 (pt)	2017-05-23	parte de distribuidor.
IT1397694B1 (it)	2013-01-24	Puntale per attacchi da sci-alpinismo.
BRPI0807001A2 (pt)	2014-04-15	Formulação farmacêutica, e, método para preparação de uma formulação farmacêutica.
BRPI0912761A2 (pt)	2015-10-13	parte de distribuidor.
BRPI0820258A2 (pt)	2017-04-04	composto, composições de vacina e farmacêutica, e , métodos para estimular uma resposta imune em um indivíduo e para tratar um indivíduo